In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).
Cesar Serrano-Garcia
No relevant relationships to disclose
Michael C. Heinrich
Consultant or Advisory Role - ARIAD; MolecularMD; Novartis; Pfizer
Stock Ownership - MolecularMD
Honoraria - Novartis; Onyx
Research Funding - Arog; Astex Therapeutics; Bayer; Novartis
Meijun Zhu
No relevant relationships to disclose
Chandrajit P. Raut
Honoraria - Novartis
Grant Eilers
No relevant relationships to disclose
Gloria Ravegnini
No relevant relationships to disclose
George D. Demetri
Consultant or Advisory Role - Bayer; Blueprint Medicines; Champions Biotechnology; Foundation Medicine; G1 Therapeutics; GlaxoSmithKline; Johnson & Johnson; Kolltan Pharmaceuticals; Merck; Merrimack; N-of-One (U); Novartis; Pfizer; Sanofi ; ZIOPHARM Oncology
Stock Ownership - Blueprint Medicines; Champions Biotechnology; G1 Therapeutics; Kolltan Pharmaceuticals; N-of-One
Research Funding - Bayer; GlaxoSmithKline; Johnson & Johnson; Merck; Novartis; Pfizer; Sanofi
Expert Testimony - Bayer (U)
Sebastian Bauer
Honoraria - Bayer; Novartis; Pfizer
Jonathan A. Fletcher
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Novartis
Suzanne George
Consultant or Advisory Role - Bayer
Research Funding - Bayer; Novartis; Pfizer